The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Slides:

Advertisements

Similar presentations

Volume 53, Issue 3, Pages (March 2008)

Advertisements

Volume 55, Issue 1, Pages 1-8 (January 2009)

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 58, Issue 4, Pages (October 2010)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 60, Issue 2, Pages (August 2011)

Volume 49, Issue 2, Pages (February 2006)

Volume 46, Issue 3, Pages (September 2004)

Volume 64, Issue 4, Pages (October 2013)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 65, Issue 5, Pages (May 2014)

Volume 70, Issue 4, Pages (October 2016)

Volume 71, Issue 5, Pages (May 2017)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 1, Pages (January 2013)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 3, Pages (March 2015)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 67, Issue 6, Pages (June 2015)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 53, Issue 6, Pages (June 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 63, Issue 3, Pages (March 2013)

Volume 62, Issue 4, Pages (October 2012)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 72, Issue 4, Pages (October 2017)

Volume 53, Issue 1, Pages (January 2008)

Volume 49, Issue 4, Pages (April 2006)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

European Urology is “Your” Journal

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Volume 51, Issue 2, Pages (February 2007)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic Value of Tumour Ploidy and Comorbidity Jan Adolfsson, Bernhard Tribukait, Seymour Levitt European Urology Volume 52, Issue 4, Pages 1028-1035 (October 2007) DOI: 10.1016/j.eururo.2007.04.002 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Metastasis-free survival and treatment-free survival in 119 patients with clinically localized prostate cancer subjected to watchful waiting. European Urology 2007 52, 1028-1035DOI: (10.1016/j.eururo.2007.04.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Disease-specific survival and overall survival in 119 patients with clinically localized prostate cancer subjected to watchful waiting. European Urology 2007 52, 1028-1035DOI: (10.1016/j.eururo.2007.04.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Disease-specific survival for patients with diploid (n=60) and nondiploid (n=58) tumours at diagnosis (one patient excluded because ploidy data were not available). European Urology 2007 52, 1028-1035DOI: (10.1016/j.eururo.2007.04.002) Copyright © 2007 European Association of Urology Terms and Conditions